Fennec Pharmaceuticals Inc. Forecast, price target & analysts
Fennec Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation
Fennec Pharmaceuticals Inc. Classifications & Recommendation:
Fennec Pharmaceuticals Inc. Price Target
| Target Price | $12.80 |
| Price | $8.17 |
| Potential |
56.67%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Fennec Pharmaceuticals Inc. 2026 .
The average Fennec Pharmaceuticals Inc. target price is $12.80.
This is
56.67%
register free of charge
$15.00
83.60%
register free of charge
$10.00
22.40%
register free of charge
|
|
| A rating was issued by 5 analysts: 5 Analysts recommend Fennec Pharmaceuticals Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fennec Pharmaceuticals Inc. stock has an average upside potential 2026 of
56.67%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 47.54 | 46.32 |
| 123.72% | 2.56% | |
| Net Margin | -1.16% | 10.01% |
| 98.51% | 962.41% |
5 Analysts have issued a sales forecast Fennec Pharmaceuticals Inc. 2025 . The average Fennec Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Fennec Pharmaceuticals Inc. 2025 . The average Fennec Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Fennec Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Fennec Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.02 | 0.17 |
| 96.67% | 950.00% | |
| P/E | 48.63 | |
| EV/Sales | 4.77 |
5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast for earnings per share. The average Fennec Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Fennec Pharmaceuticals Inc....
Current Fennec Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 20 2025 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | May 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 22 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 22 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
